Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Symyx Drug Unit Is Now Ilypsa
June 14, 2004
| A version of this story appeared in
Volume 82, Issue 24
Symyx Therapeutics, which applies high-throughput techniques to biopharmaceutical discovery, has changed its name to Ilypsa. The company has also appointed Scott M. Rocklage to be executive chairman. Rocklage is a partner in 5AM Ventures and the chairman of Cubist Pharmaceuticals. Additionally, Ilypsa, which had been working out of Symyx Technologies' facilities, is moving to its own 21,000-sq-ft space in Santa Clara, Calif. Investors in Ilypsa include the Sprout Group, Symyx Technologies, and 5AM Ventures.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter